Integrated continuous biomanufacturing: A new paradigm for biopharmaceutical production

J Biotechnol. 2015 Nov 10:213:1-2. doi: 10.1016/j.jbiotec.2015.08.015. Epub 2015 Aug 20.

Authors

Chetan T Goudar¹, Nigel Titchener-Hooker², Konstantin Konstantinov³

Affiliations

¹ Drug Substance Technologies, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA. Electronic address: cgoudar@amgen.com.
² Department of Biochemical Engineering, University College London, Gordon Street, London WC1H 0AH, UK. Electronic address: nigelth@ucl.ac.uk.
³ Late Stage Process Development, Genzyme-Sanofi, Framingham, MA 1701, USA. Electronic address: Konstantin.konstantinov@genzyme.com.

PMID: 26297904
DOI: 10.1016/j.jbiotec.2015.08.015

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Antibodies, Monoclonal
Biological Products
Biotechnology / methods*
Cell- and Tissue-Based Therapy
Drug Industry
Vaccines

Substances

Antibodies, Monoclonal
Biological Products
Vaccines